Category

Cohort News

Candesant Biomedical Announces $35M in Series B Financing to Advance Commercialization of Brella™, the First and Only FDA-cleared 3-Minute SweatControl Patch™

//
Categories
NASHVILLE, Tenn., June 6, 2023 /PRNewswire/ — Candesant Biomedical, Inc. (“Candesant”), a private medical device company focused on the development and commercialization of non-invasive treatments for hyperhidrosis or excessive sweating, today announced the closing of a Series B financing, raising...
Read More →

CORRECTING and REPLACING Universal DX Presents Data from Large, 1,000-patient, Multi-Cohort Study Proving 93% Sensitivity for Colorectal Cancer and 54% Sensitivity for Advanced Adenoma at 92% Specificity

//
Categories
Findings highlight company’s approach is highly accurate for early-stage (I-II) detection: CRCs (91% sensitivity) and AA (54% sensitivity) at 92% specificity Data offer hope for the future of blood-based early cancer detection Universal Diagnostics (Universal DX), a bioinformatics and multi-omics...
Read More →

Gaylord Specialty Healthcare First in Nation to Adopt Ground-Breaking Pharyngeal Electrical Stimulation Technology to Treat Patients with Dysphagia featuring Phagenesis

//
Categories
WALLINGFORD, Conn., May 9, 2023 /PRNewswire/ — Gaylord Specialty Healthcare, a nonprofit rehabilitation-focused healthcare system, is proud to announce that it is the first healthcare organization in the nation to use the Phagenyx® Neurostimulation System from Phagenesis, Ltd. to treat dysphagia among stroke...
Read More →